NEW YORK, June 5, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Roche Holding AG. ("Roche" or the "Company") (OTCQX:RHHBY). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rhhby.
The investigation concerns whether Roche and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 5, 2017, several news sources reported and alleged that a new study revealed that adding Roche's breast cancer drug Perjeta to the company's older treatment Herceptin only showed minor benefits while more doubling the one-year cost of treatment, and that the combination of the drugs showed an increase of certain side effects, more than Herceptin alone, including severe diarrhea. Following this news, Roche stock dropped sharply during intra-day trading on June 5, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Roche, you can assist this investigation by visiting the firm's site: www.bgandg.com/rhhby. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article